Funding for this research was provided by:
National Cancer Institute (U24 CA237617)
National Institutes of Health (U24 HG009446)
Science and Technology Commission of Shanghai Municipality (18YF1402500)
National Natural Science Foundation of China (31801110)
Received: 5 June 2019
Accepted: 13 January 2020
First Online: 7 February 2020
Ethics approval and consent to participate
: Not applicable.
: MB receives sponsored research support from Novartis. MB serves on the SAB of Kronos Bio and is a consultant to H3 Biomedicine. XSL is a cofounder and board member of GV20 Oncotherapy, SAB of 3DMed Care, consultant for Genentech, and stockholder of BMY, TMO, WBA, ABT, ABBV, and JNJ. All other authors declare that they have no competing interests.